Lupus clinical trials in Illinois
14 studies for Lupus are looking for participants at sites in Illinois.
Cities in Illinois
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Chicago
- Research Site, Chicago
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 30, 2026 · NCT05835310A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Willow Rheumatology and Wellness PLLC, Willowbrook
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 279147, Orland Park
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07607964A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Willowbrook
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 25, 2026 · NCT07430306A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
RecruitingPhase 2
Ages 16 to 70 · All sexes · Updated Sep 17, 2026 · NCT07328581A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Chicago
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 10, 2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50699, Chicago
- Sl0044 50717, Willowbrook
RecruitingPhase 3
Ages 16 and older · All sexes · Updated Sep 4, 2026 · NCT06617325A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Willow Rheumatology & Wellness, Willowbrook
RecruitingObservational study
Ages 16 and older · All sexes · Updated Sep 3, 2026 · NCT07175285A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Aug 28, 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Aug 26, 2026 · NCT06121297A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 278462, Orland Park
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 10, 2026 · NCT06977724Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Robert A Hozman MD SC, Skokie
- Willow Rheumatology Wellness, Willowbrook
RecruitingPhase 3
Ages 12 to 100 · All sexes · Updated Jul 8, 2026 · NCT06133972Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Chicago, Chicago
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Apr 15, 2026 · NCT05934149From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.